SCHEMBL23975681

SCHEMBL23975681

c1ccc(CNc2nc(-c3ccccn3)nc3c2CCC3)nc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.54
BCHE P06276 2/20 0.53
ACHE P22303 2/20 0.53
ALOX15 P16050 1/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 2/20 0.46
KDM4E B2RXH2 1/20 0.46
JAK2 O60674 1/20 0.46
RAB9A P51151 1/20 0.46
USP1 O94782 2/20 0.46
WDR48 Q8TAF3 2/20 0.46
PDE10A Q9Y233 1/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
PDE5A O76074 3/20 0.45
CFTR P13569 2/20 0.45
GFER P55789 1/20 0.45
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225282 1.00 HIF1A (0.54) HIF1ABCHEACHEALOX15CYP1A2
SCHEMBL30225331 0.82 ACHE (0.55) BCHEACHEALOX15CYP1A2CYP3A4
SCHEMBL23975678 0.82 ACHE (0.55) BCHEACHEALOX15CYP1A2CYP3A4
SCHEMBL23976252 0.81 PDE4B (0.47) HIF1ANPC1KDM4EUSP1WDR48
SCHEMBL30225366 0.81 PDE4B (0.47) HIF1ANPC1KDM4EUSP1WDR48
SCHEMBL20665835 0.81 METAP2 (0.53) HIF1AALOX15LMNAKDM4ERAB9A
SCHEMBL26225716 0.80 SMN1; SMN2 (0.46) HIF1ABCHEACHEALOX15CYP1A2
SCHEMBL23975633 0.79 PDE4B (0.52) HIF1ALMNAKDM4EKMT2AGFER
SCHEMBL30118572 0.77 NPC1 (0.44) HIF1ACYP1A2NPC1RAB9AKMT2A
SCHEMBL23976244 0.77 NPC1 (0.44) HIF1ACYP1A2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 HIF1A 253/4885BCHE 3460/4885ACHE 4830/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI HIF1A 235/4885BCHE 4033/4885ACHE 4876/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI HIF1A 235/4885BCHE 4033/4885ACHE 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.